Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I, Open-label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity in Healthy Adults of a DNA Plasmid Vaccine for H5 Avian Influenza (VGX-3400X) Administered by Intramuscular (IM) Injection Followed by Electroporation (EP).

Next Previous
X
Search
Trial Profile

Phase I, Open-label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity in Healthy Adults of a DNA Plasmid Vaccine for H5 Avian Influenza (VGX-3400X) Administered by Intramuscular (IM) Injection Followed by Electroporation (EP).

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 28 May 2012

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VGX 3400 (Primary)
  • Indications Influenza A virus H5N1 subtype
  • Focus Adverse reactions

    • Most Recent Events

    • 21 May 2012 Actual end date (1 Nov 2011) added as reported by ClinicalTrials.gov. (Parent trial: NCT01142362)
    • 16 May 2012 Status changed from active, no longer recruiting to completed, according to an Inovio Pharmaceuticals media release.
    • 30 Mar 2012 Planned end date changed from 1 Nov 2011 to 1 May 2012 as reported by ClinicalTrials.gov (Parent trial: NCT01142362).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top